ABCAM Plc Director/PDMR Shareholding (0816I)

TIDMABC

RNS Number : 0816I

ABCAM Plc

27 May 2014

 
 For immediate release   27 May 2014 
 

ABCAM PLC

("Abcam" or "the Company")

PDMR dealing

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, announces that following completion of three years of continued employment since the award of Matching Shares under the Share Incentive Plan, the risk of forfeiture attached to these shares has now been removed, resulting in an increase in the beneficial holding of the following PDMRs:

 
 Name                      Matching   Date of transfer         Total   Percentage 
                             Shares      to beneficial    subsequent     of share 
                    now transferred          ownership    beneficial      capital 
                      to beneficial                          holding 
                          ownership 
----------------  -----------------  -----------------  ------------  ----------- 
 Mark Bushfield                  29        27 May 2014         7,721       0.004% 
----------------  -----------------  -----------------  ------------  ----------- 
 Philippe 
  Cotrel                         29        27 May 2014        11,535       0.006% 
----------------  -----------------  -----------------  ------------  ----------- 
 

For further information please contact:

 
                                    + 44 (0) 1223 696 
 Abcam                               000 
 Jeff Iliffe, Chief Financial 
  Officer 
 Numis Securities - Nominated       + 44 (0) 20 7260 
  Adviser & Joint Broker             1000 
 Michael Meade - Nominated 
  Adviser 
 James Black - Corporate Broking 
 Peel Hunt LLP - Joint Broker       [phone] 
 Clare Terlouw / Jock Maxwell 
  MacDonald 
                                    + 44 (0) 20 7466 
 Buchanan                            5000 
 Mark Court / Fiona Henson 
  / Sophie Cowles 
 

Notes for editors:

About Abcam plc

Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level to improve the understanding of health and disease.

Abcam is committed to providing scientists with access to the correct reagents and tools for their research. The Company's catalogue currently comprises more than 131,000 products and is continually evolving to meet customer needs. The range offered includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam products are supported with detailed, up-to-date and unbiased data on our website.

Headquartered in Cambridge, UK, Abcam has eight global subsidiary offices and ships to over 100 countries. The Company was founded in 1998, and now employs over 700 people. Abcam is quoted on the AIM market of the London Stock Exchange (AIM: ABC).

To find out more, please visit www.abcam.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSQDLBLZEFEBBX